Julien Edeline, MD, of the Centre Eugène Marquis, discusses study findings on gemcitabine and oxaliplatin vs surveillance following surgery for localized biliary tract cancer (Abstract 225).
Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses a range of topics, including tyrosine kinase inhibitors, immune therapies, targeted approaches, and DNA damage repair strategies.
Mark Talamonti, MD, of NorthShore University Health System, discusses the technical prerequisites for minimally invasive surgery in pancreatic cancers and the potential benefits to patients.
Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses in Spanish study findings on nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (Abstract 226).
Salah-Eddin Al-Batran, MD, of the Institute of Clinical Cancer Research and Nordwest Hospital, discusses study findings on paclitaxel with and without RAD001 in patients with gastric cancer whose disease has progressed after therapy with a fluoropyrimidine/platinum-containing regimen (Abstract 4).
Julien Edeline, MD, of the Centre Eugène Marquis, discusses in French study findings on gemcitabine and oxaliplatin vs surveillance following surgery for localized biliary tract cancer (Abstract 225).
